Cancer drug developer Ideaya Biosciences has appointed Julie Hambleton to serve as senior vice president and chief medical officer, head of development. Hambleton most recently worked at Bristol-Myers Squibb (NYSE: [[ticker:BMY]]) where she was a vice president and head of the company’s U.S. medical operations. Her experience also includes executive posts at Five Prime Therapeutics (NASDAQ: [[ticker:FPRX]]) and Clovis Oncology (NASDAQ: [[ticker:CLVS]]). Ideaya, which splits its operations between South San Francisco, CA, and San Diego, is developing drugs based on synthetic lethality, an approach that targets genetic interactions of cancer cells as a way of killing them.
